Revision as of 03:04, 20 February 2023

Back to Top

Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
For placebo or observational studies in this condition, please visit this page.

9 regimens on this page 15 variants on this page

Advanced or metastatic disease, first-line

Docetaxel & Gemcitabine

Regimen variant #1, 60/675

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Hensley et al. 2015 (GOG-250)	2009-2013	Phase 3 (C)	DG & Bevacizumab	Did not meet primary endpoint of PFS

Note: This regimen was intended for patients who received prior radiation.

Chemotherapy

Docetaxel (Taxotere) 60 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 675 mg/m² IV over 70 to 90 minutes once per day on days 1 & 8, given first

21-day cycles

Regimen variant #2, 75/675

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Hensley et al. 2002	NR	Phase 2
Seddon et al. 2017 (GeDDiS)	2010-2014	Phase 3 (E-switch-ic)	Doxorubicin	Did not meet primary endpoint of alive and progression free at 24 weeks

Note: In Hensley et al. 2002, this regimen was intended for patients who received prior radiation.

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 675 mg/m² IV over 90 minutes once per day on days 1 & 8, given first

Supportive therapy

Dexamethasone (Decadron) 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after Docetaxel (Taxotere))
Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
One of the following growth factors (varies depending on reference):
- G-CSF (type not specified) 150 mcg/m² (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10

21-day cycle for 6 to 8 cycles

Regimen variant #3, 75/900

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Hensley et al. 2015 (GOG-250)	2009-2013	Phase 3 (C)	DG & Bevacizumab	Did not meet primary endpoint of PFS

Note: This regimen was intended for patients with no prior radiation.

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 900 mg/m² IV over 90 minutes once per day on days 1 & 8, given first

21-day cycles

Regimen variant #4, 100/900

Study	Years of enrollment	Evidence
Hensley et al. 2002	NR	Phase 2
Hensley et al. 2008 (GOG 87L)	2003-2006	Phase 2

Note: This regimen was intended for patients with no prior radiation.

Chemotherapy

Docetaxel (Taxotere) 100 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 900 mg/m² IV over 90 minutes once per day on days 1 & 8, given first

Supportive therapy

Dexamethasone (Decadron) 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after Docetaxel (Taxotere))
Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
One of the following growth factors (varies depending on reference):
- G-CSF (type not specified) 150 mcg/m² (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10

21-day cycle for 6 to 8 cycles; Hensley et al. 2008 did not specify a maximum number of cycles

References

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31. link to original article contains dosing details in manuscript PubMed
GOG 87L: Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun;109(3):329-34. link to original article contains dosing details in manuscript link to PMC article PubMed
GOG-250: Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 1;33(10):1180-5. Epub 2015 Feb 23. link to original article link to PMC article PubMed NCT01012297
GeDDiS: Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397-1410. Epub 2017 Sep 4. link to original article link to PMC article PubMed ISRCTN07742377

Doxorubicin monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Seddon et al. 2017 (GeDDiS)	2010-2014	Phase 3 (C)	DG	Did not meet primary endpoint of alive and progression free at 24 weeks
Pautier et al. 2022 (LMS-04)	2017-2019	Phase 3 (C)	Doxorubicin & Trabectedin	Inferior PFS

Chemotherapy

Doxorubicin (Adriamycin) 75 mg/m² IV once on day 1

21-day cycle for 6 cycles

References

GeDDiS: Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397-1410. Epub 2017 Sep 4. link to original article link to PMC article PubMed ISRCTN07742377
LMS-04: Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1044-1054. Epub 2022 Jul 11. link to original article contains dosing details in abstract PubMed NCT02997358

Doxorubicin & Trabectedin

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Pautier et al. 2022 (LMS-04)	2017-2019	Phase 3 (E-esc)	Doxorubicin	Superior PFS Median PFS: 12.2 vs 6.2 mo (HR 0.41, 95% CI 0.29-0.58)

Chemotherapy

Doxorubicin (Adriamycin) as follows:
- Cycles 1 to 6: 60 mg/m² IV once on day 1
Trabectedin (Yondelis) 1.1 mg/m² IV once on day 1

21-day cycles

References

LMS-04: Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1044-1054. Epub 2022 Jul 11. link to original article contains dosing details in abstract PubMed NCT02997358

Advanced or metastatic disease, subsequent lines of therapy

Dacarbazine monotherapy

Regimen variant #1, 850 mg/m²

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Schöffski et al. 2016 (E7389-G000-309)	2011-2013	Phase 3 (C)	Eribulin	Did not meet primary endpoint of OS¹

¹Reported efficacy is based on the 2019 subgroup analysis.

Chemotherapy

Dacarbazine (DTIC) 850 mg/m² IV over 20 to 120 minutes once on day 1

21-day cycles

Regimen variant #2, 1000 mg/m²

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Demetri et al. 2015 (ET743-SAR-3007)	2011-2013	Phase 3 (C)	Trabectedin	Did not meet primary endpoint of OS
Schöffski et al. 2016 (E7389-G000-309)	2011-2013	Phase 3 (C)	Eribulin	Did not meet primary endpoint of OS¹

¹Reported efficacy for E7389-G000-309 is based on the 2019 subgroup analysis.
Note: this is listed as a "starting dose" in Demetri et al. 2015, but no adjustment instructions were provided in the manuscript.

Chemotherapy

Dacarbazine (DTIC) 1000 mg/m² IV over 20 to 120 minutes once on day 1

21-day cycles

Regimen variant #3, 1200 mg/m²

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Schöffski et al. 2016 (E7389-G000-309)	2011-2013	Phase 3 (C)	Eribulin	Did not meet primary endpoint of OS¹

¹Reported efficacy is based on the 2019 subgroup analysis.

Chemotherapy

Dacarbazine (DTIC) 1200 mg/m² IV over 20 minutes once on day 1

Supportive therapy

Buesa et al. 1991: Calcium gluconate (10% solution) 5 mL IV every 10 minutes x 3 doses (total of 15 mL) after the start of dacarbazine; 2 additional doses of calcium gluconate (10% solution) 5 mL IV every 10 minutes were given to patients whose systolic blood pressure decreased below 80 mmHg or heart rate more than 160 bpm.

21-day cycles

References

ET743-SAR-3007: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01343277
1. Subgroup analysis: Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. link to original article link to PMC article PubMed
2. Update: Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. link to original article link to PMC article PubMed
E7389-G000-309: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. link to original article PubMed NCT01327885
1. Subgroup analysis: Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer. 2019 May;120(11):1026-1032. Epub 2019 May 8. link to original article link to PMC article PubMed

Dacarbazine & Gemcitabine

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
García-Del-Muro et al. 2011	2005-2008	Randomized Phase 2, <20 pts in this subgroup (E-esc)	Dacarbazine	Superior OS Median OS: 16.8 vs 8.2 mo (HR 0.56, 95% CI 0.36-0.90)

Chemotherapy

Dacarbazine (DTIC) 500 mg/m² IV over 20 minutes once on day 1, given second
Gemcitabine (Gemzar) 1800 mg/m² IV at fixed dosed rate over 3 hours once on day 1, given first

14-day cycle for at least 12 cycles

References

García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011 Jun 20;29(18):2528-33. Epub 2011 May 23. link to original article contains dosing details in manuscript PubMed EudraCT 2005-001709-24

Docetaxel & Gemcitabine

Regimen variant #1, 75/675

Study	Years of enrollment	Evidence
Hensley et al. 2002	NR	Phase 2

Note: This regimen was intended for patients who received prior radiation.

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 675 mg/m² IV over 90 minutes once per day on days 1 & 8, given first

Supportive therapy

Dexamethasone (Decadron) 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after Docetaxel (Taxotere))
Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
One of the following growth factors (varies depending on reference):
- G-CSF (type not specified) 150 mcg/m² (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10

21-day cycle for 6 to 8 cycles

Regimen variant #2, 100/900

Study	Years of enrollment	Evidence
Hensley et al. 2002	NR	Phase 2

Note: This regimen was intended for patients with no prior radiation.

Chemotherapy

Docetaxel (Taxotere) 100 mg/m² IV over 60 minutes once on day 8, given second
Gemcitabine (Gemzar) 900 mg/m² IV over 90 minutes once per day on days 1 & 8, given first

Supportive therapy

Dexamethasone (Decadron) 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after Docetaxel (Taxotere))
Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
One of the following growth factors (varies depending on reference):
- G-CSF (type not specified) 150 mcg/m² (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10

21-day cycle for 6 to 8 cycles

References

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31. link to original article contains dosing details in manuscript PubMed

Eribulin monotherapy

Regimen

Study

Years of enrollment

Evidence

Comparator

Comparative Efficacy

Schöffski et al. 2016 (E7389-G000-309)

ESMO-MCBS (3)

2011-2013

Phase 3 (E-switch-ic)

Dacarbazine

Did not meet primary endpoint of OS¹

¹Reported efficacy is based on the 2019 subgroup analysis.

Chemotherapy

Eribulin (Halaven) 1.4 mg/m² IV once per day on days 1 & 8

21-day cycles

References

E7389-G000-309: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. link to original article PubMed NCT01327885
1. Subgroup analysis: Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer. 2019 May;120(11):1026-1032. Epub 2019 May 8. link to original article link to PMC article PubMed

Regorafenib monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Mir et al. 2016 (REGOSARC)	2013-2014	Randomized Phase 2 (E-esc)	Placebo	Superior PFS¹ Median PFS: 3.7 vs 1.8 mo (HR 0.46, 95% CI 0.46-0.80)

¹Reported efficacy is for the leiomyosarcoma cohort.

Targeted therapy

Regorafenib (Stivarga) 160 mg PO once per day on days 1 to 21

28-day cycles

References

REGOSARC: Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. Epub 2016 Oct 14. link to original article contains dosing details in abstract PubMed NCT01900743

Trabectedin monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Demetri et al. 2009	2003-NR	Randomized Phase 2 (E-switch-ic)	Trabectedin; alternate schedule	Seems to have superior TTP
Demetri et al. 2015 (ET743-SAR-3007)	2011-2013	Phase 3 (E-RT-switch-ic)	Dacarbazine	Did not meet primary endpoint of OS

Note: in Demetri et al. 2015, this is listed as a "starting dose," but no adjustment instructions were provided in the manuscript.

Chemotherapy

Trabectedin (Yondelis) 1.5 mg/m² IV continuous infusion over 24 hours, started on day 1

Supportive therapy

Dexamethasone (Decadron) 20 mg IV once on day 1, prior to Trabectedin (Yondelis)

21-day cycles

References

Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. Epub 2009 Aug 3. link to original article contains dosing details in abstract PubMed
ET743-SAR-3007: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01343277
1. Subgroup analysis: Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. link to original article link to PMC article PubMed
2. Update: Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. link to original article link to PMC article PubMed

@@ Line 12: / Line 12: @@
 |}
 {{TOC limit|limit=3}}
 =Advanced or metastatic disease, first-line=
 ==Docetaxel & Gemcitabine {{#subobject:1e718f|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 60/675 {{#subobject:270ac9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 32: / Line 30: @@
 |-
 |}
-''This regimen was intended for patients who received prior radiation.''
+''Note: This regimen was intended for patients who received prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 675 mg/m<sup>2</sup> IV over 70 to 90 minutes once per day on days 1 & 8, '''given first'''
 '''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 75/675 {{#subobject:2898f9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 60: / Line 59: @@
 |-
 |}
-''In Hensley et al. 2002, this regimen was intended for patients who received prior radiation.''
+''Note: In Hensley et al. 2002, this regimen was intended for patients who received prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 675 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''
 ====Supportive therapy====
 *[[Dexamethasone (Decadron)]] 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after [[Docetaxel (Taxotere)]])
@@ Line 71: / Line 70: @@
 **[[:Category:Granulocyte colony-stimulating factors|G-CSF]] (type not specified) 150 mcg/m<sup>2</sup> (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
 **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10
 '''21-day cycle for 6 to 8 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #3, 75/900 {{#subobject:2a13c9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 89: / Line 88: @@
 |-
 |}
-''This regimen was intended for patients with no prior radiation.''
+''Note: This regimen was intended for patients with no prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 900 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''
 '''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #4, 100/900 {{#subobject:d89e30|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 111: / Line 111: @@
 |-
 |}
-''This regimen was intended for patients with no prior radiation.''
+''Note: This regimen was intended for patients with no prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 900 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''
 ====Supportive therapy====
 *[[Dexamethasone (Decadron)]] 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after [[Docetaxel (Taxotere)]])
@@ Line 122: / Line 122: @@
 **[[:Category:Granulocyte colony-stimulating factors|G-CSF]] (type not specified) 150 mcg/m<sup>2</sup> (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
 **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10
 '''21-day cycle for 6 to 8 cycles'''; Hensley et al. 2008 did not specify a maximum number of cycles
+</div></div>
 ===References===
 # Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31. [https://doi.org/10.1200/jco.2002.11.050 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12065559 PubMed]
@@ Line 130: / Line 129: @@
 # '''GOG-250:''' Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 1;33(10):1180-5. Epub 2015 Feb 23. [https://doi.org/10.1200/JCO.2014.58.3781 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372854/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25713428 PubMed] NCT01012297
 # '''GeDDiS:''' Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397-1410. Epub 2017 Sep 4. [https://doi.org/10.1016/S1470-2045(17)30622-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622179/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28882536 PubMed] ISRCTN07742377
 ==Doxorubicin monotherapy {{#subobject:1adg18f|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:2tsaat9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 154: / Line 152: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycle for 6 cycles'''
+</div></div>
 ===References===
 # '''GeDDiS:''' Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397-1410. Epub 2017 Sep 4. [https://doi.org/10.1016/S1470-2045(17)30622-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622179/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28882536 PubMed] ISRCTN07742377
 #'''LMS-04:''' Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1044-1054. Epub 2022 Jul 11. [https://doi.org/10.1016/s1470-2045(22)00380-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/35835135/ PubMed] NCT02997358
 ==Doxorubicin & Trabectedin {{#subobject:1agccf|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:1vhat9|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 180: / Line 177: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Doxorubicin (Adriamycin)]] as follows:
 **Cycles 1 to 6: 60 mg/m<sup>2</sup> IV once on day 1
 *[[Trabectedin (Yondelis)]] 1.1 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
 #'''LMS-04:''' Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1044-1054. Epub 2022 Jul 11. [https://doi.org/10.1016/s1470-2045(22)00380-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/35835135/ PubMed] NCT02997358
 =Advanced or metastatic disease, subsequent lines of therapy=
 ==Dacarbazine monotherapy {{#subobject:62426f|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 850 mg/m<sup>2</sup> {{#subobject:f09c3f|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 209: / Line 205: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on the 2019 subgroup analysis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Dacarbazine (DTIC)]] 850 mg/m<sup>2</sup> IV over 20 to 120 minutes once on day 1
 '''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 1000 mg/m<sup>2</sup> {{#subobject:4b5552|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 237: / Line 234: @@
 ''<sup>1</sup>Reported efficacy for E7389-G000-309 is based on the 2019 subgroup analysis.''<br>
 ''Note: this is listed as a "starting dose" in Demetri et al. 2015, but no adjustment instructions were provided in the manuscript.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Dacarbazine (DTIC)]] 1000 mg/m<sup>2</sup> IV over 20 to 120 minutes once on day 1
 '''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #3, 1200 mg/m<sup>2</sup> {{#subobject:2c183b|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 258: / Line 256: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on the 2019 subgroup analysis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Dacarbazine (DTIC)]] 1200 mg/m<sup>2</sup> IV over 20 minutes once on day 1
 ====Supportive therapy====
 *'''Buesa et al. 1991:''' Calcium gluconate (10% solution) 5 mL IV every 10 minutes x 3 doses (total of 15 mL) after the start of dacarbazine; 2 additional doses of calcium gluconate (10% solution) 5 mL IV every 10 minutes were given to patients whose systolic blood pressure decreased below 80 mmHg or heart rate more than 160 bpm.
 '''21-day cycles'''
+</div></div>
 ===References===
 # '''ET743-SAR-3007:''' Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14. [https://doi.org/10.1200/jco.2015.62.4734 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26371143 PubMed] NCT01343277
@@ Line 272: / Line 269: @@
 # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26874885 PubMed] NCT01327885
 ## '''Subgroup analysis:''' Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer. 2019 May;120(11):1026-1032. Epub 2019 May 8. [https://dx.doi.org/10.1038/s41416-019-0462-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738064/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31065111 PubMed]
 ==Dacarbazine & Gemcitabine {{#subobject:cd9068|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:9aaddf|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 290: / Line 286: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Dacarbazine (DTIC)]] 500 mg/m<sup>2</sup> IV over 20 minutes once on day 1, '''given second'''
 *[[Gemcitabine (Gemzar)]] 1800 mg/m<sup>2</sup> IV at fixed dosed rate over 3 hours once on day 1, '''given first'''
 '''14-day cycle for at least 12 cycles'''
+</div></div>
 ===References===
 # García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011 Jun 20;29(18):2528-33. Epub 2011 May 23. [https://doi.org/10.1200/JCO.2010.33.6107 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21606430 PubMed] EudraCT 2005-001709-24
 ==Docetaxel & Gemcitabine {{#subobject:1e78gu|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 75/675 {{#subobject:tj18f9|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 312: / Line 307: @@
 |-
 |}
-''This regimen was intended for patients who received prior radiation.''
+''Note: This regimen was intended for patients who received prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 675 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''
 ====Supportive therapy====
 *[[Dexamethasone (Decadron)]] 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after [[Docetaxel (Taxotere)]])
@@ Line 323: / Line 318: @@
 **[[:Category:Granulocyte colony-stimulating factors|G-CSF]] (type not specified) 150 mcg/m<sup>2</sup> (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
 **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10
 '''21-day cycle for 6 to 8 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 100/900 {{#subobject:u1ge30|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 337: / Line 332: @@
 |-
 |}
-''This regimen was intended for patients with no prior radiation.''
+''Note: This regimen was intended for patients with no prior radiation.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 8, '''given second'''
 *[[Gemcitabine (Gemzar)]] 900 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1 & 8, '''given first'''
 ====Supportive therapy====
 *[[Dexamethasone (Decadron)]] 8 mg PO twice per day on days 7 to 9 (the day before, the day of, and day after [[Docetaxel (Taxotere)]])
@@ Line 348: / Line 343: @@
 **[[:Category:Granulocyte colony-stimulating factors|G-CSF]] (type not specified) 150 mcg/m<sup>2</sup> (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC greater than 1200/uL on two separate measurements
 **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10
 '''21-day cycle for 6 to 8 cycles'''
+</div></div>
 ===References===
 # Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31. [https://doi.org/10.1200/jco.2002.11.050 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12065559 PubMed]
 ==Eribulin monotherapy {{#subobject:427859|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:2bcda0|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 365: / Line 358: @@
 |-
 |[https://doi.org/10.1016/S0140-6736(15)01283-0 Schöffski et al. 2016 (E7389-G000-309)]
+{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-202-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
+|-
+|}
 |2011-2013
 | style="background-color:#1a9851" |Phase 3 (E-switch-ic)
@@ Line 372: / Line 369: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on the 2019 subgroup analysis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV once per day on days 1 & 8
 '''21-day cycles'''
+</div></div>
 ===References===
 # '''E7389-G000-309:''' Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10. [https://doi.org/10.1016/S0140-6736(15)01283-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26874885 PubMed] NCT01327885
 ## '''Subgroup analysis:''' Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer. 2019 May;120(11):1026-1032. Epub 2019 May 8. [https://dx.doi.org/10.1038/s41416-019-0462-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738064/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31065111 PubMed]
 ==Regorafenib monotherapy {{#subobject:c9fc2c|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:b5ff4e|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 400: / Line 395: @@
 |}
 ''<sup>1</sup>Reported efficacy is for the leiomyosarcoma cohort.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Regorafenib (Stivarga)]] 160 mg PO once per day on days 1 to 21
 '''28-day cycles'''
+</div></div>
 ===References===
 # '''REGOSARC:''' Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. Epub 2016 Oct 14.  [https://doi.org/10.1016/S1470-2045(16)30507-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27751846 PubMed] NCT01900743
 ==Trabectedin monotherapy {{#subobject:cfc3ed|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:05c55d|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 432: / Line 426: @@
 |}
 ''Note: in Demetri et al. 2015, this is listed as a "starting dose," but no adjustment instructions were provided in the manuscript.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Trabectedin (Yondelis)]] 1.5 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
 ====Supportive therapy====
 *[[Dexamethasone (Decadron)]] 20 mg IV once on day 1, prior to [[Trabectedin (Yondelis)]]
 '''21-day cycles'''
+</div></div>
 ===References===
 # Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-96. Epub 2009 Aug 3. [https://doi.org/10.1200/JCO.2008.21.0088 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/19652065 PubMed]
@@ Line 445: / Line 438: @@
 ## '''Subgroup analysis:''' Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-537. Epub 2017 Jun 24. [https://doi.org/10.1016/j.ygyno.2017.06.018 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5783302/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28651804 PubMed]
 ## '''Update:''' Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 1;125(15):2610-2620. Epub 2019 Jun 7. [https://doi.org/10.1002/cncr.32117 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173362 PubMed]
 [[Category:Leiomyosarcoma regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Soft tissue sarcomas]]

Difference between revisions of "Leiomyosarcoma"

Revision as of 03:04, 20 February 2023

Advanced or metastatic disease, first-line

Docetaxel & Gemcitabine

Regimen variant #1, 60/675

Chemotherapy

Regimen variant #2, 75/675

Chemotherapy

Supportive therapy

Regimen variant #3, 75/900

Chemotherapy

Regimen variant #4, 100/900

Chemotherapy

Supportive therapy

References

Doxorubicin monotherapy

Regimen

Chemotherapy

References

Doxorubicin & Trabectedin

Regimen

Chemotherapy

References

Advanced or metastatic disease, subsequent lines of therapy

Dacarbazine monotherapy

Regimen variant #1, 850 mg/m2

Chemotherapy

Regimen variant #2, 1000 mg/m2

Chemotherapy

Regimen variant #3, 1200 mg/m2

Chemotherapy

Supportive therapy

References

Dacarbazine & Gemcitabine

Regimen

Chemotherapy

References

Docetaxel & Gemcitabine

Regimen variant #1, 75/675

Chemotherapy

Supportive therapy

Regimen variant #2, 100/900

Chemotherapy

Supportive therapy

References

Eribulin monotherapy

Regimen

Chemotherapy

References

Regorafenib monotherapy

Regimen

Targeted therapy

References

Trabectedin monotherapy

Regimen

Chemotherapy

Supportive therapy

References

Navigation menu

Search

Regimen variant #1, 850 mg/m²

Regimen variant #2, 1000 mg/m²

Regimen variant #3, 1200 mg/m²